Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.20 USD
-0.95 (-2.43%)
Updated Sep 29, 2023 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Earnings News For HALO
-
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
-
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
-
Halozyme Therapeutics: Q2 Earnings Snapshot
-
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?
-
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
-
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
-
Halozyme Therapeutics: Q1 Earnings Snapshot
-
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
-
Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates
-
Halozyme Therapeutics: Q4 Earnings Snapshot
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?
-
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
-
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
-
Halozyme Therapeutics: Q3 Earnings Snapshot
-
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Expected to Beat Earnings Estimates: Should You Buy?
-
Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook
-
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates